Altimmune (ALT) Cash from Investing Activities (2010 - 2026)

Altimmune (ALT) has 17 years of Cash from Investing Activities data on file, last reported at -$3.7 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$3.7 million, up 27.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$131.1 million (down 2272.06% YoY), and the FY2025 annual result was -$132.5 million, down 366.68% from the prior year.
• Cash from Investing Activities advanced to -$3.7 million in Q1 2026 per ALT's latest filing, from -$79.2 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $101.1 million in Q2 2025 and troughed at -$149.3 million in Q3 2025.
• A 5-year average of -$13.2 million and a median of -$3.7 million in 2026 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities soared 147900.0% in 2023, then sank 12553.79% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at $981000.0 in 2022, then tumbled by 911.31% to -$8.0 million in 2023, then jumped by 271.28% to $13.6 million in 2024, then slumped by 680.68% to -$79.2 million in 2025, then soared by 95.34% to -$3.7 million in 2026.
• Business Quant data shows ALT's Cash from Investing Activities at -$3.7 million in Q1 2026, -$79.2 million in Q4 2025, and -$149.3 million in Q3 2025.